脂肪肝
脂质代谢
代谢途径
内科学
疾病
新陈代谢
医学
生物
生物化学
作者
Olufunto O. Badmus,Sarah A. Hillhouse,Christopher D. Anderson,Terry D. Hinds,David E. Stec
出处
期刊:Clinical Science
[Portland Press]
日期:2022-09-01
卷期号:136 (18): 1347-1366
被引量:159
摘要
Abstract The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in the liver in combination with metabolic dysfunction in the form of overweight or obesity and insulin resistance. It is also associated with an increased cardiovascular disease risk, including hypertension and atherosclerosis. Hepatic lipid metabolism is regulated by a combination of the uptake and export of fatty acids, de novo lipogenesis, and fat utilization by β-oxidation. When the balance between these pathways is altered, hepatic lipid accumulation commences, and long-term activation of inflammatory and fibrotic pathways can progress to worsen the liver disease. This review discusses the details of the molecular mechanisms regulating hepatic lipids and the emerging therapies targeting these pathways as potential future treatments for MAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI